Research
Hormonal
Next-generation GLP-1 based therapies (oral formulations, small-molecule agonists, multi-receptor agonists) aim to achieve greater efficacy (>25% weight loss), improved tolerability, and novel delivery platforms.
Next-generation GLP-1 based therapies aim to achieve greater weight loss (>25%), improved tolerability, and novel delivery platforms, including oral formulations and small-molecule agonists. These therapies are currently in clinical trials and represent the future direction of obesity treatment.
GoodSupportsHIGH confidence
Current success has accelerated development of next-generation therapies targeting greater efficacy, improved tolerability, and novel delivery platforms, including oral formulations and small-molecule nonpeptide agonists.
Why this rating
Supported by Phase 2/3 trials for specific agents (Orforglipron, Survodutide, Mazdutide, CagriSema, Retatrutide).
Source
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Jang Won Son · Journal of Korean Medical Association · 2026
DOI 10.5124/jkma.25.0138
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) induce substantial weight loss (10-25%) and improve glycemic control through appetite suppression and enhanced satiety.Strong
- GLP-1 receptor agonists provide cardiovascular and renal benefits, including reduced risk of major adverse cardiovascular events (MACE) and improved heart failure symptoms, independent of weight loss.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →